Endexo (system of a hemodialysis)

2019: Announcement

At the end of October, 2019 Fresenius Medical Care provided the new system of a hemodialysis which prevents formation of blood clots. A system contains polymer under the name Endexo which reduces risk of fibrillation, that reducing the need for anticoagulants, such as heparin.

Heparin is usually used during a hemodialysis for prevention of a tromboobrazovaniye. Nevertheless, use of medicine is connected with a number of the immediate and remote ghost effects, including with decrease in quantity of platelets, osteoporosis and the high level of cholesterol.

Fresenius Medical Care provided the new system of a hemodialysis which prevents formation of blood clots

Fresenius, the largest system provider of dialysis, said that she wishes to reduce risk of these ghost effects in 2010 when signed the license agreement with Interface Biologics company. The agreement allowed Fresenius to estimate use of polymer Interface, Endexo, in the dialysis equipment and an opportunity to license technology.

Endexo was specially developed for decrease in adhesion and activation of platelets, adsorption of protein and formation of blood clots. At the same time polymer does not affect physical or functional properties of the medical device which it is built in.

Developments of Fresenius on use of this technology in a hemodialysis began to yield fruits in 2018 when the company began clinical trials of the equipment using Endexo. The research included 26 patients with a terminal stage of a renal failure.

Originally participants were treated, using Fresenius Optiflux hemodialysis device. Later they were transferred to the equipment with Endexo polymer. The efficiency and security of devices estimated on reduction of concentration of urea and on the frequency of ghost effects. Clinical trials were complete at the beginning of 2019, and Fresenius should provide results of a research by the end of the year.^[1]

Notes